Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.

Journal of medical virology - 1 Jan 2018

Schnell Gretja, Tripathi Rakesh, Krishnan Preethi, Beyer Jill, Reisch Thomas, Irvin Michelle, Dekhtyar Tatyana, Setze Carolyn, Rodrigues Lino, Alves Katia, Burroughs Margaret, Redman Rebecca, Chayama Kazuaki, Kumada Hiromitsu, Collins Christine, Pilot-Matias Tami

Abstract excerpt

Treatment of HCV genotype (GT) 2-infected Japanese patients with paritaprevir (NS3/4A inhibitor boosted with ritonavir) and ombitasvir (NS5A inhibitor) without ribavirin for 12 weeks in the phase 2 study M12-536, and with ribavirin for 16 weeks in phase 3 study GIFT II resulted in SVR rates of 72.2% to 91.5%. Overall, 11 out of 125 patients with GT2a and 37 out of 79 patients with GT2b infection experienced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anilides
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Lactams, Macrocyclic

Share to Macrocyclic Compounds

Share to Ritonavir

Share to Sulfonamides

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 28842997
DOI: 10.1002/jmv.24923
PMCID: PMC6680211

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.PMID 28842997Read ↗

Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and OmbitasvirSemantic proximity Read ↗

Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.Semantic proximity Read ↗

Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.Semantic proximity Read ↗

Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir.Semantic proximity Read ↗

Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.Semantic proximity Read ↗

Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.Semantic proximity Read ↗

HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1bSemantic proximity Read ↗

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.Semantic proximity Read ↗

HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials.Semantic proximity Read ↗

Peginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.